Thomas Gajewski, MD, PhD
Thomas Gajewski, MD, PhD, investigates and develops new treatments for patients with melanoma. He has a special interest in the development of immunotherapies against this disease. Dr. Gajewski also leads development of immune-based therapies for other cancers, using new laboratory data on how the immune system is regulated to develop novel clinical trials.
Dr. Gajewski serves as an editor for Cancer Research and Journal for Immunotherapy of Cancer. In addition, he is immediate past president of the Society for Immunotherapy of Cancer and has served on the program committees for the American Society for Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR).
Associated Articles
Thomas Gajewski, MD, PhD, University of Chicago Material Contribution to Immuno-Oncology
Thomas Gajewski, MD, PhD, AbbVie Foundation Professor of Cancer Immunotherapy in the Ben May Department for Cancer Research and Professor of Pathology and Medicine at the University of Chicago, was named by the European Society for Medical Oncology (ESMO) as the...
Popular Posts
0 Comments